Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ligalli B V is active in the Medical Devices & Mechanical Engineering technology area with 3 pending office actions. These actions are distributed across 3 distinct examiners, which means each pending application is being reviewed by a different individual. This variety of examiners can lead to different prosecution experiences for each matter in the portfolio.
The portfolio's work is spread across 2 distinct art units. This indicates that the company's medical device technologies are diverse enough to be categorized into two different technical areas by the patent office. MERCIER, MELISSA S is the busiest examiner for the portfolio, with 1 pending office action. This examiner's workload is one of three equal parts of the total pending actions.
The workload is evenly balanced, as the busiest examiner is responsible for 1 of the 3 total pending actions. This distribution ensures that no single examiner has a dominant influence on the portfolio's progress. Practitioners should be prepared to navigate the requirements of 2 distinct art units and the individual styles of three separate examiners. This structure requires a flexible strategy to manage the different technical and examiner-specific demands.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MERCIER, MELISSA S | 1 | 72.1% | +5.8% |
| DOUGHERTY, SEAN PATRICK | 1 | 74.7% | +15.7% |
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.6% | +53.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18802794 | Vaginal Drug Delivery Device | MERCIER, MELISSA S | — |
| 18699071 | Tumor Markers | DOUGHERTY, SEAN PATRICK | — |
| 18274646 | Treatment of Overactive Bladder with Oxybutynin Applied By Means of a Vaginal Ring | RAMACHANDRAN, UMAMAHESWARI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18699071 | Tumor Markers | DOUGHERTY, SEAN PATRICK | — |
| 18274646 | Treatment of Overactive Bladder with Oxybutynin Applied By Means of a Vaginal Ring | RAMACHANDRAN, UMAMAHESWARI | — |
| Art Unit | Apps |
|---|---|
| 3791 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18802794 | Vaginal Drug Delivery Device | MERCIER, MELISSA S | — | §102§103§112 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18699071 | Tumor Markers | DOUGHERTY, SEAN PATRICK | 3791 | §103§112 | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18274646 | Treatment of Overactive Bladder with Oxybutynin Applied By Means of a Vaginal Ring | RAMACHANDRAN, UMAMAHESWARI | 1627 | §102§112Other | Non-Final OA | — | Pending | Jul 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial